TC-5619

DRUG3 trials

Sponsors

Targacept Inc.

Conditions

Alzheimer's DiseaseCognitive DysfunctionNegative SymptomsSchizophrenia

Phase 1

Multiple Ascending Dose Study of TC-5619 in Healthy Elderly Subjects and Subjects With Alzheimer's Disease

CompletedNCT01254448

Targacept Inc.Alzheimer's Disease

Start: 2010-09-30End: 2011-05-31Updated: 2013-09-04

Phase 2

TC-5619 as Augmentation Therapy to Improve Cognition in Outpatients With Cognitive Dysfunction in Schizophrenia

CompletedNCT01003379

Targacept Inc.Cognitive Dysfunction, Schizophrenia

Start: 2009-10-31End: 2010-12-31Updated: 2013-09-13

Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia

CompletedNCT01488929

Targacept Inc.Cognitive Dysfunction, Negative Symptoms, Schizophrenia

Start: 2011-12-31End: 2013-11-30Updated: 2015-06-03